Cipher Pharmaceuticals (TSE:CPH) Given a C$17.00 Price Target by Canaccord Genuity Group Analysts

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) has been assigned a C$17.00 price objective by research analysts at Canaccord Genuity Group in a research report issued on Tuesday,BayStreet.CA reports. The brokerage currently has a “hold” rating on the stock. Canaccord Genuity Group’s price target would indicate a potential downside of 6.03% from the company’s previous close.

Cipher Pharmaceuticals Trading Down 0.9%

Shares of CPH stock traded down C$0.16 on Tuesday, hitting C$18.09. The stock had a trading volume of 29,714 shares, compared to its average volume of 31,041. Cipher Pharmaceuticals has a twelve month low of C$11.87 and a twelve month high of C$20.56. The firm has a market cap of C$457.33 million, a P/E ratio of 17.23 and a beta of 0.89. The company has a current ratio of 1.25, a quick ratio of 2.67 and a debt-to-equity ratio of 0.32. The company has a fifty day moving average price of C$17.39 and a two-hundred day moving average price of C$15.59.

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) last announced its quarterly earnings results on Thursday, May 7th. The company reported C$0.33 earnings per share (EPS) for the quarter. Cipher Pharmaceuticals had a net margin of 60.82% and a return on equity of 25.69%. The company had revenue of C$17.39 million during the quarter. As a group, analysts forecast that Cipher Pharmaceuticals will post 1.2907348 earnings per share for the current fiscal year.

Cipher Pharmaceuticals Company Profile

Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products, mainly in dermatology. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and currently markets those products in Canada, the U.S., and South America.